<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055131</url>
  </required_header>
  <id_info>
    <org_study_id>913</org_study_id>
    <nct_id>NCT02055131</nct_id>
  </id_info>
  <brief_title>Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis</brief_title>
  <official_title>a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tunis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tunis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study consisting in testing whether systematic use of aspirin is
      beneficial for primary prevention of vascular access for hemodialysis attested by doppler
      ultrasound exam. The investigators will study aspirin resistance in the population of
      patients undergoing hemodialysis. The investigators will test sensibility of resistant
      patients to aspirin dose escalation. PFA-100 is the biologic test used in this study to
      define aspirin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three groups of dialysed patients will be included in this study. The first is the placebo
      group, the second is the aspirin group fixed dose and the last group includes patients
      receiving a dose of aspirin titrated by the result of PFA-100.

      At the end of this study the investigators will be able to identify whether systematic
      antiaggregation is suitable for a vascular access for hemodialysis. The investigators will
      also conclude which is better for patients fixed dose or aspirin dose escalation determined
      by the result of PFA-100. The study will analyse the prevalence of aspirin resistant patients
      in this particular population of dialysed patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of fistula thrombosis in patients receiving a dose of aspirin titrated by the result of PFA-100 compared to placebo and fixed dose aspirin</measure>
    <time_frame>1 year</time_frame>
    <description>patients undergoing hemodialysis via native fistula will receive either placebo or aspirin titrated dose by the PFA-100 or aspirin fixed dose to prevent thrombosis of the access .the follow up period will be fixed at 1 year and all thromboembolic complications of the access will be noted</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of aspirin resistant patients even to aspirin escalation dose titrated by PFA-100 in the population of dialysed patients.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence and severity of aspirin complications in dialysed patients</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>aspirn fixed dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin dose titrated with PFA-100</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>in this group of patients we will just supervise thromboembolic events of the vascular access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <arm_group_label>aspirn fixed dose</arm_group_label>
    <arm_group_label>aspirin dose titrated with PFA-100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dialysed patients

          -  vascular access aged less than one year

          -  no serious complication of the vascular access previously such as hemorrhagic
             complication and tight stenosis

        Exclusion Criteria:

          -  pregnant and breastfeeding women

          -  patients receiving at baseline other antiaggregant or anticoagulant

          -  patient not allowed to be treated by aspirin

          -  systolic blood pressure&gt; 200 mmhg

          -  diastolic blood pressure&gt;115 mmhg

          -  liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nouira Samir, professor</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>clinical and medical investigation in emergency medecine laboratry,hospitalo-university center of Monastir</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manel Ben Salah, nephrologist</last_name>
      <phone>+216 55 928 869</phone>
      <email>manell_bs@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sabra Aloui, professor</last_name>
      <phone>+216 92453822</phone>
      <email>alouisabra@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>asma fradi, assistant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manel Ben Salah, nephrologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabra Aloui, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tunis University</investigator_affiliation>
    <investigator_full_name>Ben Salah Manel</investigator_full_name>
    <investigator_title>nephrologist</investigator_title>
  </responsible_party>
  <keyword>vascular access</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>aspirin resistance</keyword>
  <keyword>PFA-100</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

